Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer†
Corresponding Author
Mitsuhiko Kawashima MD
Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, JapanSearch for more papers by this authorRyuichi Hayashi MD
Head and Neck Surgery Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorMakoto Tahara MD
Gastrointestinal Medical Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorSatoko Arahira MD
Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorMasakazu Miyazaki MD
Head and Neck Surgery Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorMinoru Sakuraba MD
Plastic and Reconstructive Surgery Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorSadamoto Zenda MD
Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorTakashi Ogino MD
Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorCorresponding Author
Mitsuhiko Kawashima MD
Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, JapanSearch for more papers by this authorRyuichi Hayashi MD
Head and Neck Surgery Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorMakoto Tahara MD
Gastrointestinal Medical Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorSatoko Arahira MD
Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorMasakazu Miyazaki MD
Head and Neck Surgery Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorMinoru Sakuraba MD
Plastic and Reconstructive Surgery Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorSadamoto Zenda MD
Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorTakashi Ogino MD
Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
Search for more papers by this authorThis work was presented at the 46th Annual Meeting of the American Society of Clinical Oncology (abstract #5576).
Abstract
Background
Altered fractionation radiotherapy (RT) improves locoregional control in head and neck cancer without aggravation of late adverse events. To improve successful larynx-preservation rates in patients with resectable, intermediate-volume hypopharyngeal cancer, a prospective trial of chemotherapy-enhanced accelerated RT was conducted.
Methods
Patients with T2 to T4 hypopharyngeal cancer received 40 Gray (Gy)/4 weeks to the entire neck followed by boost RT administering 30 Gy/2 weeks (1.5 Gy twice-daily fractionation). Cisplatin and 5-fluorouracil were administered concomitantly only during boost RT.
Results
Thirty-five patients were enrolled in this study. All patients completed this protocol as planned. After a median follow-up period for surviving patients of 59 months (24–90 months), overall survival and local control rates at 3 years were 91% (95% confidence interval, 81% to 100%), and 88% (79% to 99%), respectively. All surviving patients maintained normalcy of diets.
Conclusion
This regimen was feasible with encouraging oncological and functional outcomes. © 2011 Wiley Periodicals, Inc. Head Neck, 2011
REFERENCES
- 1 Cancer Registry Committee of the Japan Society for Head and Neck Cancer: report of head and neck cancer registry of Japan. Clinical statistics of registered patients, 2003. Jpn J Head Neck Cancer 2006; 32 Suppl: 7–20.
- 2 Matsuda T, Marugame T, Kamo K, et al. Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. Jpn J Clin Oncol 2008; 38: 641–648.
- 3 Lefebvre JL, Chevalier D, Lubinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996; 88: 890–899.
- 4 Hall SF, Groome PA, Irish J, et al. Radiotherapy or surgery for head and neck squamous cell cancer: establishing the baseline for hypopharyngeal carcinoma? Cancer 2009; 115: 5711–5722.
- 5 Yoshimura R, Kagami Y, Ito Y, et al. Outcomes in patients with early-stage hypopharyngeal cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2010; 77: 1017–1023.
- 6 Nakamura K, Shioyama Y, Kawashima M, et al. Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65: 1045–1050.
- 7 Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362: 933–940.
- 8 Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variations of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7–16.
- 9 Foote RL. Radiotherapy alone for early stage squamous cell carcinoma of the larynx and hypopharynx. Int J Radiat Oncol Biol Phys 2007; 69( Suppl): S31–S36.
- 10 Mendenhall WM. Outcomes after surgery or definitive radiotherapy for hypopharyngeal cancer. Cancer 2009; 115: 5620–5622.
- 11
Garden AS,
Morrison WH,
Clayman GL,
Ang KK,
Peters LJ.
Early squamous cell carcinoma of the hypopharynx: outcomes of treatment with radiation alone to the primary disease.
Head Neck
1996;
18:
317–322.
10.1002/(SICI)1097-0347(199607/08)18:4<317::AID-HED2>3.0.CO;2-0 CAS PubMed Web of Science® Google Scholar
- 12 Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4–14.
- 13 Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582–3589.
- 14 Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 2006; 24: 2636–2643.
- 15 Lee WT, Akst LM, Adelstein DJ, et al. Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation. Head Neck 2006; 28: 808–812.
- 16 Dörr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol 2001; 61: 223–231.
- 17 Pfister DG, Laurie SA, Weinstein GS, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006; 24: 3693–3704.
- 18 Spector JG, Sessions DG, Haughey BH, et al. Delayed regional metastasis, distant metastasis, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope 2001; 111: 1079–1087.
- 19 Kawashima M, Ogino T, Fujii H, et al. Local-regional control by conventional radiotherapy according to tumor volume in patients with squamous cell carcinoma of the pharyngolarynx. Jpn J Clin Oncol 1999; 29: 467–473.
- 20 Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131–146.
- 21
Ang KK,
Peters LJ.
Concomitant boost radiotherapy in the treatment of head and neck cancers.
Semin Radiat Oncol
1992;
2:
31–33.
10.1016/S1053-4296(05)80049-9 Google Scholar
- 22 Kawashima M, Hayashi R, Tahara M, et al. Accelerated radiotherapy and larynx preservation in favorable-risk patients with T2 or worse hypopharyngeal cancer. Jpn J Clin Oncol 2007; 37: 345–352.
- 23 Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987; 13: 403–426.
- 24 Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 1994; 12: 2648–2653.
- 25 The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685–1690.
- 26 Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091–2098.
- 27 Chen SW, Yang SN, Liang JA, et al. Prognostic impact of tumor volume in patients with stage III–IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy. Head Neck 2009; 31: 709–716.
- 28 Hoebers FJ, Pameijer FA, de Bois J, et al. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma. Head Neck 2008; 30: 1216–1233.
- 29 Rasch C, Steenbakkers R, van Herk M. Target definition in prostate, head, and neck. Semin Radiat Oncol 2005; 15: 136–145.
- 30 Dubben HH, Thames HD, Beck–Bornholdt HP. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol 1998; 47: 167–174.
- 31 Kamiyama R, Saikawa M, Kishimoto S. Significance of retropharyngeal lymph node dissection in hypopharyngeal cancer. Jpn J Clin Oncol 2009: 632–637.
- 32 Stoeckli SJ, Pawlik AB, Lipp M, Huber A, Schmid S. Salvage surgery after failure of nonsurgical therapy for carcinoma of the larynx and hypopharynx. Arch Otolaryngol Head Neck Surg 2000; 126: 1473–1477.
- 33 Goodwin WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000; 110( Suppl 93): 1–18.
- 34 Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy — results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1161–1171.
- 35 Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99–14. J Clin Oncol 2005; 23: 3008–3015.
- 36 Garden AS, Asper JA, Morrison WH, et al. Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma? Cancer 2004; 100: 1171–1178.
- 37 Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100( 9 Suppl): 1995–2025.
- 38 Byers RM, Clayman GL, Guillamondequi OM, Peters LJ, Goepfert H. Resection of advanced cervical metastasis prior to definitive radiotherapy for primary squamous carcinomas of the upper aerodigestive tract. Head Neck 1992; 14: 133–138.
- 39
Verschuur HP,
Keus RB,
Hilgers FJ,
Balm AJ,
Gregor RT.
Preservation of function by radiotherapy of small primary carcinomas preceded by neck dissection for extensive nodal metastases of the head and neck.
Head Neck
1996;
18:
277–282.
10.1002/(SICI)1097-0347(199605/06)18:3<277::AID-HED10>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 40 Reddy AN, Eisele DW, Forastiere AA, Lee DJ, Westra WH, Califano JA. Neck dissection followed by radiotherapy or chemoradiotherapy for small primary oropharynx carcinoma with cervical metastasis. Laryngoscope 2005; 115: 1196–1200.
- 41 Cupino A, Axelrod R, Anne PR, et al. Neck dissection followed by chemoradiotherapy for stage IV (N+) oropharynx cancer. Otolaryngol Head Neck Surg 2007; 137: 416–421.
- 42 Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A, Bosq J. Lymph node prognostic factor in head and neck squamous cell carcinomas. Am J Surg 1994; 168: 494–497.
- 43 Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 843–854.
- 44 Ang KK, Zhang Q, Wheeler RH, et al. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome. J Clin Oncol 2010; 28: 7s (suppl; abstr 5507).
- 45 Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 2005; 23: 79–87.
Citing Literature
